Publications & Reports

Attitudes toward and experience with naloxone among people who use drugs in the Southeastern United States.
Le MH, Laschober TC, Tross S, Paschen-Wolff M, Ertl MM, Wright L, Hatch MA.
International Journal of Drug Policy 2025; 139:10479.

Substance use and mental health symptoms in adults with prenatal alcohol exposure.
Hunnicut-Ferguson K, Stoner SA, Kable JA, Grant TM, Coles CD.
Neurotoxicology and Teratology 2025 (in press).

Pharmacy staff-reported adaptations to naloxone provision and over-the-counter (OTC) syringe sales during the COVID-19 pandemic: Experiences across multiple states and 2 pharmacy chains.
Green TC, Silcox J, Boliver D, Gray M, Floyd AS, et al.
Journal of the American Pharmacists Association 2024;64(1):71-78.

Community-based medications first for opioid use disorder – Care utilization and mortality outcomes.
Banta-Green CJ, Owens MD, Williams JR, Floyd AS, Williams-Gilbert W, Kingston S.
Substance Abuse & Rehabilitation 2024;15:173-183. Watch the video abstract!

Results from the 2024 WA State Permanent Supportive Housing Perceptions and Community Health Survey.
Petersky S, Banta-Green CJ.
Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, September 2024.

Language Matters: Cannabis and Tobacco Use Among Youth of Diverse Racial/Ethnic Backgrounds.
Carlini BH, Harwick RH, Williams JR.
Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, July 2024.

Criminal justice staff’s professional quality of life and interactions with justice-involved individuals: The moderating role of stigma.
Siebert SL, Owens MD, Folk JB, Moore KE. Deviant Behavior 2024 (in press).

State requirements for non-medical US cannabis retail personnel.
LoParco C, Cui Y, McCready D, Romm KF, Yang TY, Rossheim ME, Carlini B, Vinson K, Cavazos-Rehg P, Berg CJ.
Journal of Public Health Management & Practice 2024 (in press).

The cost of safe injection: Insights on nonprescription syringe price variability from systematic secret shopping.
Blough MJ, Rocha A, Bratberg J, Silcox J, Bolivar D, Floyd AS, Gray M, Green TC.
Substance Use & Addiction Journal 2024;45(2):201-210.

Results from the 2023 WA State Syringe Services Program Health Survey.
Kingston S, Newman A, Banta-Green C, Glick S.
Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, April 2024.

Adapting to the fentanyl epidemic: Rapid qualitative observations and derived clinical and research implications from the Emergency Department Longitudinal Integrated Care (ED-LINC) randomized clinical trial.
Lovett K, Zatzick D, … Banta-Green CJ, Whiteside LK.
Psychiatry 2025 (in press).

Factors associated with PrEP awareness and use among men who have sex with men who use drugs in the Southern United States.
Paschen-Wolff MM, Tross S, Nelson CM, Hatch MA, Meche D, Ertl MM, Wright L, Laschober TC.
AIDS Care 2024 (in press).

Willingness to Use Oral and Long-Acting Injectable PrEP in Substance-Using Men Who Have Sex with Men (SU-MSM) in High HIV Incidence Southern U.S. Cities: A NIDA Clinical Trials Network Study.
Tross S, Laschober TC, Paschen-Wolff M, Ertl M, Nelson CM, Wright L, Lancaster C, Feaster DJ, Monger M, Toal P, Fegley JP, Meche D, Hankey C, Woodhouse C, Spector A, Dresser L, Moran L, Jelstrom E, Haynes LF, Shoptaw S, Hatch MA.
AIDS & Behavior 2024 (in press).

Washington State Drug Brief: BTMPS – A New Substance Found in Community Drug Checking Samples.
CEDEER. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, September 2024.

Development and exploratory evaluation of substance use and substance use disorder training for the Washington State Basic Law Enforcement Academy.
Owens MD, McKee M, Rickert C, Rogel B, Starnes B. Policing 2024;18:paae091.

Policies, adaptations, and ongoing challenges to naloxone, buprenorphine and nonprescription syringe access across four-states: Findings from an environmental scan and key informant interviews.
Floyd AS, Silcox J, Strickler G, Nong T, Blough M, Bolivar D, Rabin M, Bratberg J, Irwin AN, Hartung DM, Hansen RN, Bohler R, Green TC.
Drug and Alcohol Dependence Reports 2024;11:100243.

Expanding access to medications for opioid use disorder: Federal policy is only a part of the solution [editorial].
Heidari O, Banta-Green CJ.
American Journal of Public Health 2024;114(7):693-695.

Program director reports of COVID-19 lockdown-driven service changes in community-based STI clinics and syringe services programs in the southeastern U.S.
Hatch MA, Laschober TC, Ertl MM, Paschen-Wolff MM, Norman G, Wright L, Tross S.
AIDS Educ Prev 2024;36(2):129-40.

“I go out of my way to give them an extra smile now”: A study of pharmacists who participated in Respond to Prevent, a community pharmacy intervention to accelerate provision of harm reduction materials.
Irwin AN, Gray M, Ventricelli D, Boggis JS, Bratberg J, Floyd AS, et al.
Research in Social and Administrative Pharmacy 2024;20(5):512-519.

Threaten, distract, and discredit: cannabis industry rhetoric to defeat regulation of high THC cannabis products in Washington State, USA.
Carlini BH, Kellum LB, Garrett SB, Nims LN.
Journal of Studies on Alcohol and Drugs 2024 (in press).